How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence?

Journal of Cardiology

Volumn 62, Issue 6, 2013, Pages 331-335

  Salgado, João Victor ^a   Souza, Francival Leite ^a   Salgado, Bernardete Jorge ^a  

^a FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

Author keywords

Cardiovascular disease; Cystatin C; Cysteine protease; Inflammation; Kidney disease

Indexed keywords

CYSTATIN C;

ADVERSE OUTCOME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; NONHUMAN; REVIEW;

CARDIOVASCULAR DISEASE; CYSTATIN C; CYSTEINE PROTEASE; INFLAMMATION; KIDNEY DISEASE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYSTATIN C; HUMANS; PROGNOSIS; RENAL INSUFFICIENCY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84892430987     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.05.015     Document Type: Review

References (49)

1. Salgado J.V., Neves F.A., Bastos M.G., Franca A.K., Brito D.J., Santos E.M., Salgado Filho N. Monitoring renal function: measured and estimated glomerular filtration rates - a review. Braz J Med Biol Res 2010, 43:528-536.
2. Lassus J., Harjola V.P., Cystatin C. A step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2012, 17:251-261.
3. Yetkin E., Waltenberger J. Cathepsin enzymes and cystatin C: do they play a role in positive arterial remodeling?. Stroke 2009, 40:e26-e27.
4. Cheng X.W., Huang Z., Kuzuya M., Okumura K., Murohara T. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011, 58:978-986.
5. Li X., Liu Z., Cheng Z., Cheng X. Cysteinyl cathepsins: multifunctional enzymes in cardiovascular disease. Chonnam Med J 2012, 48:77-85.
6. Lohoefer F., Reeps C., Lipp C., Rudelius M., Zimmermann A., Ockert S., Eckstein H.H., Pelisek J. Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall. Int J Exp Pathol 2012, 93:252-258.
7. Shi G.P., Sukhova G.K., Grubb A., Ducharme A., Rhode L.H., Lee R.T., Ridker P.M., Libby P., Chapman H.A. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999, 104:1191-1197.
8. Lindholt J.S., Erlandsen E.J., Henneberg E.W. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001, 88:1472-1475.
9. Sukhova G.K., Wang B., Libby P., Pan J.H., Zhang Y., Grubb A., Fang K., Chapman H.A., Shi G.P. C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein e-null mice. Circ Res 2005, 96:368-375.
10. Bengtsson E., To F., Hakansson K., Grubb A., Branen L., Nilsson J., Jovinge S. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25:2151-2156.
11. Puddu P., Puddu G.M., Cravero E., Vizioli L., Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol 2012, 59:235-242.
12. Xie L., Terrand J., Xu B., Tsaprailis G., Boyer J., Chen Q.M. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res 2010, 87:628-635.
13. Schulte S., Sun J., Libby P., Macfarlane L., Sun C., Lopez-Ilasaca M., Shi G.P., Sukhova G.K. C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice. Am J Pathol 2010, 177:456-463.
14. Jasir A., Kasprzykowski F., Kasprzykowska R., Lindstrom V., Schalen C., Grubb A. New antimicrobial cystatin C-based peptide active against gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus and multiresistant coagulase-negative staphylococci. APMIS 2003, 111:1004-1010.
15. Eriksson P., Deguchi H., Samnegard A., Lundman P., Boquist S., Tornvall P., Ericsson C.G., Bergstrand L., Hansson L.O., Ye S., Hamsten A. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 2004, 24:551-557.
16. Eriksson P., Jones K.G., Brown L.C., Greenhalgh R.M., Hamsten A., Powell J.T. Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms. Br J Surg 2004, 91:86-89.
17. Albert M.A., Rifai N., Ridker P.M. Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med 2001, 6:145-149.
18. Salgado J.V., Franca A.K., Cabral N.A., Lages J., Ribeiro V.S., Santos A.M., Salgado B.J. Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension. Rev Assoc Med Bras 2013, 59:21-27.
19. Dent T.H. Predicting the risk of coronary heart disease. II. The role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction. Atherosclerosis 2010, 213:352-362.
20. Urbonaviciene G., Shi G.P., Urbonavicius S., Henneberg E.W., Lindholt J.S. Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis 2011, 216:440-445.
21. Loew M., Hoffmann M.M., Koenig W., Brenner H., Rothenbacher D. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arterioscler Thromb Vasc Biol 2005, 25:1470-1474.
22. Lee M., Saver J.L., Huang W.H., Chow J., Chang K.H., Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes 2010, 3:675-683.
23. Gu F.F., Lu S.Z., Chen Y.D., Zhou Y.J., Song X.T., Jin Z.N., Liu H. Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin Med J (Engl) 2009, 122:2820-2826.
24. Batra A., Kapoor A., Sharma R.K., Agrawal N., Sinha A., Kumar S., Garg N., Tewari S., Goel P.K. Association of plasma cystatin C levels with angiographically documented coronary artery disease in patients of Indian origin. J Cardiol 2012, 59:182-189.
25. Imai A., Komatsu S., Ohara T., Kamata T., Yoshida J., Miyaji K., Shimizu Y., Takewa M., Hirayama A., Deshpande G.A., Takahashi O., Kodama K. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. Atherosclerosis 2011, 218:350-355.
26. Niccoli G., Conte M., Della Bona R., Altamura L., Siviglia M., Dato I., Ferrante G., Leone A.M., Porto I., Burzotta F., Brugaletta S., Biasucci L.M., Crea F. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis 2008, 198:373-380.
27. Shlipak M.G., Praught M.L., Sarnak M.J. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006, 15:270-275.
28. Astor B.C., Shafi T., Hoogeveen R.C., Matsushita K., Ballantyne C.M., Inker L.A., Coresh J. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis 2012, 59:653-662.
29. Skalska A., Klimek E., Wizner B., Gasowski J., Grodzicki T. Kidney function and thickness of carotid intima-media complex in patients with treated arterial hypertension. Blood Press 2007, 16:367-374.
30. Han L., Bai X., Lin H., Sun X., Chen X.M. Lack of independent relationship between age-related kidney function decline and carotid intima-media thickness in a healthy Chinese population. Nephrol Dial Transplant 2010, 25:1859-1865.
31. Monteiro F.D., Ferreira P.A., Nunes J.A., Cunha Junior C.P., Brito R.L., Costa J.H., Lima J.R., Lages J.S., Salgado Filho N., Lima V.C.AT Correlation between serum cystatin C and markers of subclinical atherosclerosis in hypertensive patients Arq Bras Cardiol 2012, 99:899-906.
32. Grubb A., Bjork J., Nyman U., Pollak J., Bengzon J., Ostner G., Lindstrom V. Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest 2011, 71:145-149.
33. Okura T., Jotoku M., Irita J., Enomoto D., Nagao T., Desilva V.R., Yamane S., Pei Z., Kojima S., Hamano Y., Mashiba S., Kurata M., Miyoshi K., Higaki J. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol 2010, 14:584-588.
34. Taglieri N., Koenig W., Kaski J.C. Cystatin C and cardiovascular risk. Clin Chem 2009, 55:1932-1943.
35. Lima J.R., Salgado J.V., Ferreira T.C., Oliveira M.I., Santos A.M., Salgado Filho N. Cystatin C and inflammatory markers in kidney transplant recipients. Rev Assoc Med Bras 2011, 57:347-352.
36. Salgado J.V., Salgado B.J., Neves F.A. Cystatin C may better reflect the effect of obesity on renal function. Obesity 2012, 20:1136.
37. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3:1-150.
38. Peralta C.A., Weekley C.C., Li Y., Shlipak M.G. Occult chronic kidney disease among persons with hypertension in the United States: data from the national health and nutrition surveys 1988-1994 and 1999-2002. J Hhypertens 2013, 31:1196-1202.
39. Bassand J.P., Hamm C.W., Ardissino D., Boersma E., Budaj A., Fernandez-Aviles F., Fox K.A., Hasdai D., Ohman E.M., Wallentin L., Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1598-1660.
40. Abisi S., Burnand K.G., Humphries J., Waltham M., Taylor P., Smith A. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br J Surg 2008, 95:333-337.
41. Doganer Y.C., Aydogan U., Aydogdu A., Aparci M., Akbulut H., Nerkiz P., Turker T., Cayci T., Barcin C., Saglam K. Relationship of cystatin C with coronary artery disease and its severity. Coron Artery Dis 2013, 24:119-126.
42. Young J.A., Hwang S.J., Sarnak M.J., Hoffmann U., Massaro J.M., Levy D., Benjamin E.J., Larson M.G., Vasan R.S., O'Donnell C.J., Fox C.S. Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol 2008, 3:1786-1791.
43. Navab K.D., Elboudwarej O., Gharif M., Yu J., Hama S.Y., Safarpour S., Hough G.P., Vakili L., Reddy S.T., Navab M., Vaziri N.D. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease. Curr Pharm Des 2011, 17:17-20.
44. Smith G.L., Lichtman J.H., Bracken M.B., Shlipak M.G., Phillips C.O., DiCapua P., Krumholz H.M. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47:1987-1996.
45. Ronco C., McCullough P., Anker S.D., Anand I., Aspromonte N., Bagshaw S.M., Bellomo R., Berl T., Bobek I., Cruz D.N., Daliento L., Davenport A., Haapio M., Hillege H., House A.A., et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010, 31:703-711.
46. Sledzinski T., Proczko-Markuszewska M., Kaska L., Stefaniak T., Swierczynski J. Serum cystatin C in relation to fat mass loss after bariatric surgery. Pol Przegl Chir 2012, 84:202-207.
47. Naour N., Fellahi S., Renucci J.F., Poitou C., Rouault C., Basdevant A., Dutour A., Alessi M.C., Bastard J.P., Clement K., Guerre-Millo M. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring) 2009, 17:2121-2126.
48. Inker L.A., Schmid C.H., Tighiouart H., Eckfeldt J.H., Feldman H.I., Greene T., Kusek J.W., Manzi J., Van Lente F., Zhang Y.L., Coresh J., Levey A.S. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012, 367:20-29.
49. Rule A.D., Bailey K.R., Lieske J.C., Peyser P.A., Turner S.T. Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney Int 2013, February 20 [Epub ahead of print].